Fabry disease, due to an inherited defect in the enzyme enzyme alpha galactosidase A, causes kidney failure in most males and about 1 in 6 females with this disease by resulting in the accumulation of the glycosphingolipid globotriaosylceramide (GL-3) in lysozymes of kidney cells. Once kidney disease is clinically manfest with substantial increases in urinary protein, treatment using enzyme replacement therapy (ERT) frequently cannot stop progression towards kidney failure. Some cells in the filters of the kidney (glomeruli) clear quickly including endothelial and mesangial cells. The podocytes (PC), on the outside of the glomerular filter, are crucial for maintaining the filter's barrier to protein leakage into the urine and loss of PC leads to scarring of glomeruli with resultant loss of filtering function and kidney failure. Unfortunately the poorly replicating PC clear poorly of their GL-3 content with ERT. There are data supporting that earlier ERT initiation may result in better PC GL-3 clearance with ERT. Delayed or inadequate (low ERT dose) treatment, we posit, leads to PC injury and death, and when PC loss becomes critical, glomecular scarring.
Our aims are to 1) determine the effect of age on PC GL-3 content and PC numbers in males and females with Fabry disease. 2) study the effects of age of ERT initiation, gender, duration of treatment and ERT dose on PC and other renal cell GL-3 clearance in children and adults with Fabry disease. 3) evaluate the effects age of initiation, gender duration and dose of ERT on PC foot process width, an important indicator of PC injury and correlate of proteinura. 4) evaluate the effects of age of ERT initiation of ERT on PC number in Fabry disease males. We will have access to the world's largest collection of kidney biopsies performed before and at various times after ERT initiation in Fabry disease male and female adult and pediatric patients with ERT given at variable dose and for variable duration. We have a world class renal morphometry laboratory and will use quantitative electron microscopic measurement tools that we have developed to accurately estimate the kidney structural variables mentioned above.

Public Health Relevance

Our studies will strongly contribute to new standards of care regarding age of institution and dose of ERT in persons with Fabry disease. Moreover our data from will help in the design of and power analyses for clinical trials testing new Fabry disease treatments. This is especially true for add on therapies to ERT where residual PC GL-3 will be the treatment target, since other renal cells will have cleared with ERT alone.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
2U54NS065768-06
Application #
8907048
Study Section
Special Emphasis Panel (ZTR1-CI-8 (01))
Program Officer
Morris, Jill A
Project Start
Project End
Budget Start
2014-09-30
Budget End
2015-07-31
Support Year
6
Fiscal Year
2014
Total Cost
$66,588
Indirect Cost
$22,780
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Mauer, Michael; Glynn, Emily; Svarstad, Einar et al. (2014) Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease. PLoS One 9:e112188
Rumsey, Robin K; Rudser, Kyle; Delaney, Kathleen et al. (2014) Acquired autistic behaviors in children with mucopolysaccharidosis type IIIA. J Pediatr 164:1147-1151.e1
Schiffmann, Raphael; Forni, Sabrina; Swift, Caren et al. (2014) Risk of death in heart disease is associated with elevated urinary globotriaosylceramide. J Am Heart Assoc 3:e000394
Polgreen, Lynda E; Thomas, William; Fung, Ellen et al. (2014) Low bone mineral content and challenges in interpretation of dual-energy X-ray absorptiometry in children with mucopolysaccharidosis types I, II, and VI. J Clin Densitom 17:200-6
Polgreen, Lynda E; Thomas, William; Orchard, Paul J et al. (2014) Effect of recombinant human growth hormone on changes in height, bone mineral density, and body composition over 1-2 years in children with Hurler or Hunter syndrome. Mol Genet Metab 111:101-6
Stevenson, David A; Rudser, Kyle; Kunin-Batson, Alicia et al. (2014) Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI. J Pediatr Rehabil Med 7:159-65
Prater, Sean N; Banugaria, Suhrad G; Morgan, Claire et al. (2014) Letter to the Editors: Concerning "CRIM-negative Pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy" by Al Khallaf et al. J Inherit Metab Dis 37:141-3
Schiffmann, Raphael; Mayfield, Joan; Swift, Caren et al. (2014) Quantitative neuroimaging in mucolipidosis type IV. Mol Genet Metab 111:147-51
Wang, Raymond Y; Braunlin, Elizabeth A; Rudser, Kyle D et al. (2014) Carotid intima-media thickness is increased in patients with treated mucopolysaccharidosis types I and II, and correlates with arterial stiffness. Mol Genet Metab 111:128-32
Ahmed, Alia; Whitley, Chester B; Cooksley, Renee et al. (2014) Neurocognitive and neuropsychiatric phenotypes associated with the mutation L238Q of the *-L-iduronidase gene in Hurler-Scheie syndrome. Mol Genet Metab 111:123-7

Showing the most recent 10 out of 34 publications